title: Difficulties in reaching therapeutic goals for hypertension and dysplipidaemia in patients with type 2 diabetes in general practice.
abstract: BACKGROUND
  National guidelines recommend strict control of blood pressure (BP) and plasma low-density lipoprotein cholesterol (LDL) in type 2 diabetes (T2DM), aiming at a BP ≤ 130/80 mmHg and an LDL concentration ≤ 2.5 mmol/l. Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II-receptor blockers (ARB) are recommended as primary antihypertensive therapy (AHT). To which extent these targets are met in Danish primary care is unknown.
  
  
  METHODS
  This study was based on data from 2,057 patients with T2DM who were randomly selected from 64 general practitioners (GPs) from different regions of Denmark. Data were collected from the GPs' electronic records.
  
  
  RESULTS
  The mean age ± standard deviation was 66.2 ± 11.6 years; 58.7% were male. The mean systolic BP ± standard deviation was 132.6 ± 14.6 mmHg and the mean diastolic BP ± standard deviation was 78.1 ± 9.0 mmHg. 47.7% of the patients met the BP target. 79.5% of the patients were on AHT. 55.1% of the untreated and 46.0% of the treated patients met the BP target. 83.4% of the treated patients received ACEI or ARB. The median LDL was 2.2 (1.7-2.7) mmol/l. 63.7% of the patients met the LDL target. 73.7% of the patients received lipid-lowering therapy. 32.8% of the untreated and 74.4% of the treated patients met the LDL target.
  
  
  CONCLUSIONS
  AHT including ACEI and ARB and lipid-lowering therapy are widely used in T2DM in Danish primary care, but only half of the patients are at target for BP and two thirds are at target for LDL. Increased use of diuretics may improve BP control.
  
  
  BACKGROUND
  This study was funded by a grant from Boehringer Ingelheim, Denmark. The grant covered costs related to data collection, time spent by the general practitioners and data analysis by the DTU.
  
  
  BACKGROUND
  not relevant.
authors.affiliation: Medicinsk Endokrinologisk Afdeling MEA, Aarhus Universitetshospital, 8000 Aarhus C, Denmark. stk@dadlnet.dk.
authors.forename: Søren Tang
authors.initials: ST
authors.lastname: Knudsen
authors.forename: Thomas Hammershaimb
authors.initials: TH
authors.lastname: Mosbech
authors.forename: Birtha
authors.initials: B
authors.lastname: Hansen
authors.forename: Else
authors.initials: E
authors.lastname: Kønig
authors.forename: Peter Christian
authors.initials: PC
authors.lastname: Johnsen
authors.forename: Anne-Lise
authors.initials: AL
authors.lastname: Kamper
mesh_terms: D000368:Aged; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure; D008078:Cholesterol, LDL / Q000097:blood; D003718:Denmark; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D005260:Female; D058006:General Practice; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010347:Patient Care Planning; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents